This year’s innovation prize from the Metropolregion Mitteldeutschland goes to a team that has brought a novel anti-tuberculosis compound all the way from basic research to clinical studies – largely funded by public grants. The winners are Dr Florian Kloß from the Leibniz Institute for Natural Product Research and Infection Biology – Hans-Knoell-Institute (HKI), Dr Julia Dreisbach from the Ludwig-Maximilians-Universität München (LMU) and Dr Uwe Müller, CEO of HAPILA GmbH.
The antibiotic candidate identified at HKI has a new and unique mode of action with strong potential to combat tuberculosis caused by multidrug-resistant pathogens. Phase I trials have successfully been completed, and a phase II study is currently being prepared.
Ascenion, the HKI’s technology transfer partner, has managed all IP-relevant aspects of the project throughout the years and helped structure all partnership agreements.
See HKI’s press release (German)